Xospata savings card: as little as $0 a prescription with commercial insurance

How to pay the least

Ask for the cash price

Xospata

We didn’t find one.

Ask your pharmacy for Xospata’s cash price, and one or two other pharmacies too.
Xospata’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify XOSPATA Patient Assistance Program (Astellas Patient Assistance Program). Meet the program financial eligibility requirements Or call 1-844-632-9272.

See if you qualify

Compare every option

Brand nameXospata

Authorized genericgilteritinib

Regular genericgilteritinib

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldNone found

Same as Xospata?

The original

–

Brand nameThe maker’s card

XOSPATA Patient Savings Program

Savings card from Astellas

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 a prescription

The card takes up to $7,000 a year off your co-pay.

Or call 1-844-632-9272.

In the maker’s words

“Patients may pay as little as $0 per prescription…”

From the maker’s offer on astellaspharmasupportsolutions.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Xospata itself, from the same company, sold without the brand name, and usually for less. For now Xospata is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

Acute myeloid leukemia (AML) with a FLT3 mutation

What the FDA label says

XOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.

Source: the FDA label for Xospata (Astellas Pharma US, Inc.), October 1, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/xospata/